Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Capital Expenditures (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Capital Expenditures for 6 consecutive years, with -$4.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 230.28% year-over-year to -$4.9 million, compared with a TTM value of $10.7 million through Dec 2025, up 58.3%, and an annual FY2025 reading of $4.6 million, up 232.78% over the prior year.
  • Capital Expenditures was -$4.9 million for Q4 2025 at Roivant Sciences, down from $7.8 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $11.2 million in Q4 2021 and bottomed at -$4.9 million in Q4 2025.
  • Average Capital Expenditures over 5 years is $3.5 million, with a median of $2.8 million recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 687.95% in 2025, while the deepest fall reached 230.28% in 2025.
  • Year by year, Capital Expenditures stood at $11.2 million in 2021, then dropped by 0.94% to $11.1 million in 2022, then plummeted by 90.67% to $1.0 million in 2023, then skyrocketed by 266.7% to $3.8 million in 2024, then tumbled by 230.28% to -$4.9 million in 2025.
  • Business Quant data shows Capital Expenditures for ROIV at -$4.9 million in Q4 2025, $7.8 million in Q3 2025, and $4.0 million in Q2 2025.